Choose Your Country or Region

Bafilomycin A1 (Baf-A1)

Name: Bafilomycin A1 (Baf-A1)
Brand: Selleck Chemicals
SKU: S1413
Rating: 5 (309 reviews)

Catalog No.S1413

For research use only.

Bafilomycin A1(Baf-A1) is a vacuolar H⁺-ATPase inhibitor with IC50 of 0.44 nM. Bafilomycin A1 is found to inhibit autophagy while induces apoptosis.

Bafilomycin A1 (Baf-A1) Chemical Structure

CAS No. 88899-55-2

Selleck's Bafilomycin A1 (Baf-A1) has been cited by 309 publications

Purity & Quality Control

Choose Selective Proton Pump Inhibitors

Related Compound Libraries

Other Proton Pump Products

Elacridar (GF120918)^New

Elacridar (GF120918, GW120918, GG918, GW0918) is a potent P-gp (MDR-1) and BCRP inhibitor.
Verdinexor (KPT-335)^New

Verdinexor (KPT-335, ATG-527) is an orally bioavailable, selective XPO1/CRM1 inhibitor.
Lansoprazole

Lansoprazole (A-65006, AG-1749) is a proton-pump inhibitor (PPI) that binds covalently to parietal cell H(+),K(+)-ATPase. Lansoprazole prevents the stomach from producing gastric acid.
Omeprazole

Omeprazole is a proton pump inhibitor that blocks H(+)-K(+)-ATPase, used to treat dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger–Ellison syndrome.
NEXIUM (esomeprazole magnesium)

Esomeprazole Magnesium is a proton pump inhibitor to reduce gastric acid secretion through inhibition of H(+)/K(+)-ATPase in gastric parietal cells.
PF-3716556

PF 3716556 is a potent and selective P-CAB (potassium-competitive acid blocker), with pIC50 of 6.026 and 7.095 for the inhibition of porcine H⁺,K⁺-ATPase activity in ion-leaky and ion-tight assay, respectively, inhibits gastric acid secretion, displays no activity at Na⁺,K⁺-ATPase, used for the treatment of gastroesophageal reflux disease.
Zinc Pyrithione

Zinc pyrithione (OM-1563) is an antifungal and antibacterial agent disrupting membrane transport by blocking the proton pump.
Dexlansoprazole

Dexlansoprazole (T 168390, TAK 390), the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties. Dexlansoprazole selectively suppresses gastric acid secretion by direct inhibition of the H(+),K(+)-ATPase proton pump in the gastric parietal cell.
Tenatoprazole

Tenatoprazole (TU-199) is a prodrug of the proton pump inhibitor (PPI) class, which inhibits proton transport with IC50 of 3.2 μM. Tenatoprazole labels only the gastric H(+),K(+)-ATPase alpha-subunit, approximately 2.6 nM/mg of tenatoprazole is bound to the H(+),K(+)-ATPase.

Download Inhibitor Catalog

Proton Pump Signaling Pathway Map

Biological Activity

Description

Bafilomycin A1(Baf-A1) is a vacuolar H⁺-ATPase inhibitor with IC50 of 0.44 nM. Bafilomycin A1 is found to inhibit autophagy while induces apoptosis.

Targets

H+-ATPase ^[1]
(Cell-free assay)

0.44 nM

In vitro

Bafilomycin A1 is a toxic macrolide antibiotic derived from Streptomyces griseus. Bafilomycin A1 inhibits the short circuit current induced by the outer mantle epithelium (OME). The IC50 and maximum inhibition dose of Bafilomycin A1 are 0.17 μM and 0.5 μM, respectively. ^[2] In addition, Bilomycin A1 inhibits the acid influx with an IC50 value of 0.4 nM. Bafilomycin A1 inhibits the acidification dose-dependently resulting in a lower quenching, and thus a higher fluorescence. ^[3] Bafilomycin A1 prevents the vacuolization of Hela cells induced by H. pylori, with an inhibitory concentration giving 50% of maximal (ID50) of 4 nM. Bafilomycin A1 is also very efficient in restoring vacuolated cells to a normal appearance. ^[4] Bafilomycin A1 also affects the transport of endocytosed material from early to late endocytic compartments. Bafilomycin not only dissipates the low endosomal pH but also blocks transport from early to late endosomes in HeLa cells. ^[5] Bafilomycin A1 at doses of 0.1-1 μM completely inhibits the acidification of lysosomes revealed by the incubation with acridine orange in BNL CL.2 and A431 cells. ^[6] When Bafilomycin A1 is added to Hanks' balanced salt solution, endogenous protein degradation is strongly inhibited and numerous autophagosomes accumulated in H-4-II-E cells. Bafilomycin A1 also prevents the appearance of endocytosed HRP in autophagic vacuoles. ^[7]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

human H4 cells	M2LrSWZ2dmO2aX;uJIF{e2G7	NF7QPWMxNjRizszN	M2jlWFI1KGh?	MoLFTY5lfWO2aX;uJI9nKGyrZ3j0JINp[WmwIEOtS2ZRKGyndnXsJIlvKGi3bXHuJGg1KGOnbHzzJIF1KDBwNDD1UUBi\nSncjCyOEBpenNiYomgbIlocCC2aILveYdpeHW2IH\seY9z\XOlZX7j[UBucWO{b4Pjc5B6KHKnbHH0bZZmKHSxIHPvcpRzd2x?	NILvXmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOECyOFU5PCd-MUiwNlQ2QDR:L3G+
RAW 264.7 cells	MYPGeY5kfGmxbjDhd5NigQ>?	NHPT[5gyODBibl2=		NIr2bHRCdnSrbXnjdo9jcWGuIHHjeIl3cXS7IHHnZYlve3RiU3HscY9v\WyuYTDlcpRmemmlYTDUfZBpcW23cnn1cUAyPDB{ODDpcoZm[3SnZDDpckBTSVdiMk[0Mlch[2WubIOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4VlKG6rdILpZ{BwgGmmZTDwdo9lfWO2aX;uJIlvKGmwZnXjeIVlKGOnbHzzJIF1KDFyMDDuUS=>	NIDhUlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUOwO\|M2QSd-MUmzNFc{PTl:L3G+
mouse RAW264.7 cells	MorERZBweHSxc3nzJIF{e2G7	M1jRfVExOCCwTR?=	MkWxNVYhcA>?	NY\seFc4UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBud3W\|ZTDSRXczPjRwNzDj[YxteyCjc4Pld5Nm\CCjczDsZZRmKGGyb4D0c5Rq[yClZXzsd{BifCBzMECgcm0h[W[2ZYKgNVYhcHK\|IIXzbY5oKGGwbnX4bY4hXi2ycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oKGK7IH\sc5ch[3m2b33leJJ6	M{DpdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{C3N\|U6Lz5zOUOwO\|M2QTxxYU6=
human HeLa cells	NFvYZ4FHfW6ldHnvckBie3OjeR?=	MWi0NFAhdk1?		M1THNmlv\HWldHnvckBw\iCjdYTvdIhi\3liaX6gbJVu[W5iSHXMZUBk\WyuczDlfJBz\XO\|aX7nJGVITlBvTFOzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIFzDN{0zKGyndnXsJIF1KDRyMDDuUS=>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN7MUm0PUc,OTh\|OUG5OFk9N2F-
human MCF7 cells	MlrBSpVv[3Srb36gZZN{[Xl?		NUHvPYpUPCCq	NVrDPVJHUW6qaXLpeIlwdiCxZjDyZZBidXmlaX6tbY5lfWOnZDDheZRweGijZ4mgbY4hcHWvYX6gUWNHPyClZXzsd{BmgHC{ZYPzbY5oKEWJRmCtUGM{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJGVITlBibHX2[Yx{KGG2IEGwNEBvVSCjZoTldkA1KGi{czDifUBY\XO2ZYLuJIJtd3S2aX7nJJJmdGG2aY\lJJRwKGOxboTyc4w>	NHvMcmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MECyPFE{PCd-MkCwNlgyOzR:L3G+
RAW 264.7 cells	M2\LeWJi[3SncnnjbYRidCCjY4Tpeol1gSCjc4PhfS=>	NVzSRY95OTByIH7N	NWfX[WRMOTZiaB?=	NEXUUWlD[WO2ZYLpZ4ll[WxiYXP0bZZqfHliYXfhbY5{fCCVYXztc45mdGyjIHXueIVzcWOjIGT5dIhqdXW{aYXtJFE1ODJ6IHnu[oVkfGWmIHnuJHJCXyB{NkSuO{Bk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCkYXP0[ZJq[WxiZ4Lve5RpKHmrZXzkJIF1KDFyMDDuUUBi\nSncjCxOkBpenNicH;zeIlv\mWldHnvckBjgSCobH;3JIN6fG:vZYTyfUBqdiCycnXz[Y5k\SCxZjCxNEB2\y:vbDDv[kBqdnS{YXPlcIx2dGG{IILldIxq[2G2aX;uJIlvcGl?	NFfYV\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUOwO\|M2QSd-MUmzNFc{PTl:L3G+
RAW 264.7 cells	NGrsd\|lCdnSrbXnjdo9jcWGuIHHjeIl3cXS7IHHzd4F6	MUexNFAhdk1?		MUjBcpRqdWmlcn;ibYFtKGGldHn2bZR6KGGpYXnud5QhW2GubX;u[Yxt[SCnboTldolk[SCWeYDobY12emm3bTCxOFAzQCCrbn\lZ5Rm\CCrbjDSRXchOjZ2LkegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3XkJI5qfHKrYzDvfIll\SCycn;keYN1cW:wIHnuJIlv\mWldHXkJINmdGy\|IHH0JFExOCCwTR?=	NILFT3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUOwO\|M2QSd-MUmzNFc{PTl:L3G+
RAW 264.7 cells	MUXBcpRqdWmlcn;ibYFtKGGldHn2bZR6KGG\|c3H5	M4W2SFExOCCwTR?=	MXKzNEBucW6\|	M1zCXWFvfGmvaXPyc4Jq[WxiYXP0bZZqfHliYXfhbY5{fCCVYXztc45mdGyjIHXueIVzcWOjIGT5dIhqdXW{aYXtJFE1ODJ6IHnu[oVkfGWmIHnuJHJCXyB{NkSuO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHLhZ5RmemmjbDDy[ZBtcWOjdHnvckBifCBzMECgcm0hfHKnYYTl[EA{OCCvaX7zJIJm\m:{ZTDpcoZm[3Srb36gcYVie3W{ZXSgZYZ1\XJiMjD0c{AyPiCqcoOgdI9{fGmwZnXjeIlwdiCkeTDmcI94KGO7dH;t[ZRzgQ>?	NEDxbGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUOwO\|M2QSd-MUmzNFc{PTl:L3G+
rat 3Y1 cells	NGrvPJNHfW6ldHnvckBie3OjeR?=			M{nIVmlv\HWldHnvckBw\iCvb4LwbI9td2erY3HsJINp[W6pZYOgbY4hemG2IEPZNUBk\WyuczDhd5Nme3OnZDDhd{BmdG:wZ3H0bY9vKG:oIHPlcIx{	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTdyMUm2N{c,Ojl5MEG5OlM9N2F-
human Huh7.5.1 cells	NHzsT21CdnSrdnnyZYwh[WO2aY\peJk>		NGXz[lk{KGh?	MULBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDIR3Yh\2Wwb4T5dIUhOmFiSl\IMVEhcW5iaIXtZY4hUHWqNz61MlEh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKG:oII\pdoFtKGWwdIL5JJVxKHSxIEOgbJJ{KGK7IHz1Z4ln\XKjc3WgZZN{[Xl?	NV7sXodlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVY3QDNpPkK2N\|k3Pjh\|PD;hQi=>

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	Ret / EGFR / p75 NGFR	21559479
Growth inhibition assay	Cell viability	20534000
Immunofluorescence	AIF ; LC3	25512644 24532803
ELISA	TNF-alpha	26240140

In vivo

Bafilomycin A1 (1 μM and 0.1 μM) completely inhibits the resorptive activity of cultured osteoclasts. ^[8] Bafilomycin A1 dose-dependently inhibits the rate of Na+ uptake in young tilapia with a Ki of 0.16 μM. ^[9]

Protocol (from reference)

Kinase Assay: ^[2]	ATPase enzyme activity assays: The ATPase enzyme assay medium contains 6 mM MgSO₄, 50 mM HEPES (pH 7.4), 200 mM Na₂SO₃ (V-ATPase activator), 0.5 mM sodium ortho-vanadate (P-ATPase inhibitor), 0.5 mM sodium azide (F-ATPase inhibitor) and 3 mM Na₂ATP. This medium (1.0 mL), with or without the addition of the V-type ATPase inhibitor bafilomycin A1, is incubated with the filtered homogenate (0.1 mL) for 60 minutes at 23–25 °C. The reaction is stopped by the addition of 1 mL of TCA 3%. Spectrometric blanks are prepared as for the enzyme assay with the exception that the tissue sample is added after the acid. Phosphate analysis is accomplished by adding 2 mL of 1-butanol and 0.2 mL molybdate solution (5 g ammonium molybdate, 22 mL H₂SO₄ to 100 mL). After vortexing for 15 seconds the solution is neutralised with 0.5 mL citrate solution (100 g/500 mL, pH 7.0) and again vortexed for 15 seconds. The solution is then centrifuged (2000 × g; 3 minutes) to separate the butanol phase and the absorbance of this phase is read at 400 nm. Standards of orthophosphate are prepared (0.1 μM–2.0 μM) and treated in the same way as the enzyme activity assays. Enzyme activity is expressed in μmol of orthophosphate liberated per hour and per milligram of protein. V-ATPase activity is considered to be the difference between the total ATPase activity measured in the presence of Na₂SO₃, sodium orthovanadate and sodium azide and the ATPase activity measured in the presence of these reagents and of the specific V-ATPases inhibitor Bafilomycin A1.
Cell Research: ^[4]	Cell lines: HeLa cells Concentrations: ~20 nM Incubation Time: 20 hours Method: H. pylori bacteria extract is treated with inhibitors, before addition to HeLa cells, as follows: DCCD 10 mM for 1 hour at 30 ºC; NBD-CI 100 μM for 1 hour at 30 ºC and the reaction is blocked with glycine 10 mM final concentration; NEM 275 μM for 1 hour at 30 ºC and the reaction is blocked by addition of β-mercaptoethanol 275 mM; Mg-ATP 14 μM for 1 hour at 0 ºC; 100 μM KNO₃ and 14 μM Mg-ATP for 1 hour at 30 μM; NaCO₃ 100 μM, pH 11 for 1 hour at 0 ºC. The bacterial extract is then added to cell with a 40-fold dilution at a final concentration of 0.65 mg/mL. Controls are HeLa cells incubated with untreated bacterial extracts and cells treated with inhibitor Bafilomycin A1 under the same conditions as bacterial extracts, at the same concentrations or after a 40-fold dilution. The vacuotating activity of the bacterial extracts is assayed.
Animal Research: ^[9]	Animal Models: Young (approximately 9 days old) Mozambique tilapia, Oreochromis mossambicus Dosages: 10 μM Administration: --

References

+ Expand

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight	622.83
Formula	C₃₅H₅₈O₉
CAS No.	88899-55-2
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	CC1CC(=CC=CC(C(OC(=O)C(=CC(=CC(C1O)C)C)OC)C(C)C(C(C)C2(CC(C(C(O2)C(C)C)C)O)O)O)OC)C

Download Bafilomycin A1 (Baf-A1) SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
How to dissolve it？

Answer:
S1413 Bafilomycin A1(Baf-A1) is soluble in DMSO at 6 mg/ml. Please do not use alcohols as solvent, because this compound will degrade in alcohols.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):